Competitive intelligence on
small-molecule drugs and
the 80,000 global patents
covering them

Start your free trial now

No commitment — No credit card required

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: GEMZAR

« Back to Dashboard

Summary for Tradename: GEMZAR

Patents:0
Applicants:1
NDAs:1
Suppliers: see list1

Pharmacology for Tradename: GEMZAR

Clinical Trials for: GEMZAR

Gleevec and Gemzar in Patients With Epithelial Ovarian Cancer
Status: Completed Condition: Ovarian Cancer; Primary Peritoneal Cancer

Intrathecal Gemcitabine to Treat Neoplastic Meningitis, IT Gemcitabine
Status: Terminated Condition: Meningitis; Neoplasms

Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)
Status: Recruiting Condition: Pancreatic Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Endocrine Gland Neoplasms; Pancreatic Diseases; Digestive System Diseases; Endocrine System Diseases; Gemcitabine; Antimetabolites, Antineoplastic

PP-Gemcitabine & External Beam Radiation-Sarcomas
Status: Active, not recruiting Condition: Sarcoma

Gemcitabine/Clofarabine/Busulfan and Allogeneic Transplantation for Aggressive Lymphomas
Status: Recruiting Condition: Lymphoma

A Study Comparing AZD-1775 (MK-1775) and Gemcitabine With Gemcitabine Alone in Ovarian, Peritoneal or Fallopian Tube Cancers
Status: Not yet recruiting Condition: Epithelial Ovarian Carcinoma; Primary Peritoneal Carcinoma; Fallopian Tube Carcinoma; Platinum-resistant; Platinum-refractory

Safety Study of ABT-263 in Combination With Gemzar (Gemcitabine) in Subjects With Solid Tumors
Status: Completed Condition: Solid Tumors

Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors
Status: Active, not recruiting Condition: Solid Tumor; Urethral Cancer

Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast Cancer
Status: Active, not recruiting Condition: Metastatic Breast Cancer

Gemcitabine Pharmacokinetics After Preoperative Chemoradiation Therapy
Status: Recruiting Condition: Pancreatic Cancer

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lilly
GEMZAR
gemcitabine hydrochloride
INJECTABLE;INJECTION020509May 15, 1996RXYes<disabled><disabled>
This preview shows a limited data set
Subscribe for full access , or try a free trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: GEMZAR

Drugname Dosage Strength RLD Submissiondate
gemcitabineFor Injection2 g/vialGemzar8/24/2007
gemcitabineFor Injection1g/vialGemzar11/14/2005
gemcitabineFor Injection200 mg/vialGemzar11/1/2005
« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology

`abc